Your browser is no longer supported. Please, upgrade your browser.
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own9.05% Shs Outstand123.73M Perf Week-4.61%
Market Cap897.04M Forward P/E- EPS next Y-0.38 Insider Trans-0.67% Shs Float122.82M Perf Month23.93%
Income-37.50M PEG- EPS next Q-0.14 Inst Own90.50% Short Float32.44% Perf Quarter21.44%
Sales55.50M P/S16.16 EPS this Y60.00% Inst Trans3.09% Short Ratio7.77 Perf Half Y57.61%
Book/sh0.18 P/B40.28 EPS next Y34.50% ROA-22.50% Target Price13.00 Perf Year10.69%
Cash/sh1.66 P/C4.37 EPS next 5Y20.00% ROE-247.50% 52W Range3.11 - 9.37 Perf YTD19.64%
Dividend- P/FCF33.72 EPS past 5Y28.10% ROI-28.80% 52W High-18.57% Beta2.56
Dividend %- Quick Ratio7.10 Sales past 5Y253.90% Gross Margin- 52W Low145.34% ATR0.57
Employees47 Current Ratio7.10 Sales Q/Q2577.90% Oper. Margin-55.00% RSI (14)59.85 Volatility8.42% 9.69%
OptionableYes Debt/Eq3.76 EPS Q/Q100.00% Profit Margin-67.60% Rel Volume3.93 Prev Close7.25
ShortableYes LT Debt/Eq3.76 EarningsFeb 25 BMO Payout- Avg Volume5.13M Price7.63
Recom1.60 SMA206.27% SMA5023.78% SMA20038.11% Volume6,309,663 Change5.24%
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-02-10Initiated Jefferies & Co Buy $12
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $14
Mar-13-09Reiterated Lazard Capital Mkts Buy $13 → $10
Apr-03-08Initiated Cowen & Co Outperform
Feb-06-08Initiated Lazard Capital Buy
Feb-04-08Reiterated Canaccord Adams Buy $29 → $32
Jan-03-08Initiated JP Morgan Overweight
Oct-03-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
Jun-07-07Initiated JP Morgan Overweight
Jun-06-07Initiated JMP Securities Mkt Outperform $26
Mar-27-15 11:23AM  Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Orexigen Therapeutics, Inc. GlobeNewswire +5.24%
10:25AM  U.S. stocks on track for big weekly loss at MarketWatch
08:25AM  Ahead of the Bell: Orexigen shares rise
Mar-26-15 08:54PM  Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers
04:32PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
03:13PM  Orexigen gets approval to market weight loss drug in Europe
02:22PM  Orexigen's Mysimba Approved in Europe for the Treatment of Obesity PR Newswire
Mar-25-15 01:17PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX GlobeNewswire
11:54AM  OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire
Mar-24-15 09:35AM  Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Announced by Shareholders Foundation GlobeNewswire
Mar-23-15 11:30AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Mar-20-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire -5.39%
09:45PM  IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal Securities Class Action Has Been Filed Against Orexigen Therapeutics, Inc. GlobeNewswire
Mar-18-15 04:54PM  Can Orexigen Win Where Obesity-Drug Rivals Failed? at Investopedia
09:30AM  Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases
Mar-16-15 02:10PM  INVESTOR ALERT: Investigation of Orexigen Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
09:54AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX Marketwired
09:11AM  Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire
Mar-14-15 07:37PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Orexigen Therapeutics, Inc. (OREX) to Contact the Firm Marketwired
05:00AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Orexigen Therapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- OREX GlobeNewswire
Mar-12-15 06:53PM  Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Orexigen Therapeutics, Inc. PR Newswire
11:19AM  Investor Class Action Filed by Barrack, Rodos & Bacine Against Orexigen Therapeutics, Inc. ("OREX") GlobeNewswire
Mar-11-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX GlobeNewswire -5.07%
07:30PM  Harwood Feffer LLP Announces Investigation of Orexigen Therapeutics, Inc. PR Newswire
05:26PM  Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Orexigen Therapeutics, Inc. Stockholders Business Wire
02:27PM  EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Against Orexigen Therapeutics, Inc. Seeking to Recover Investor Losses - OREX Business Wire
02:08PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Orexigen Therapeutics, Inc. and Certain Officers -- OREX GlobeNewswire
12:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX GlobeNewswire
11:52AM  Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Orexigen Therapeutics, Inc. PR Newswire
Mar-10-15 10:00PM  Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Orexigen Therapeutics, Inc. Business Wire
12:10AM  Did Orexigen Make A Big Mistake? at Investopedia
Mar-09-15 05:06PM  Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog Zacks
01:46PM  Nasdaq stocks posting largest percentage decreases AP
10:16AM  What Should FDA do About the Orexigen Data Disclosure? Take our Poll at The Wall Street Journal
Mar-06-15 11:01PM  OREXIGEN SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Orexigen Therapeutics, Inc. Business Wire -11.36%
03:44PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Orexigen Therapeutics, Inc. Business Wire
02:56PM  Analyst: FDA Won't Pull Permit On Orexigen Therapeutics Benzinga
11:39AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orexigen Therapeutics, Inc. - OREX PR Newswire
10:02AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. PR Newswire
08:52AM  Ahead of the Bell: Orexigen Therapeutics shares retreat AP
Mar-05-15 05:55PM  Orexigen falls after hours CNBC -5.65%
05:28PM  Top FDA Official Says Orexigen Study Result 'Unreliable,' 'Misleading' at Forbes
02:02PM  Orexigen 'Crying All The Way To The Bank' After 'Egregiously Unethical' Actions at Forbes
01:29PM  Nasdaq stocks posting largest percentage increases AP
11:27AM  Takeda Disagrees With Orexigen Over Data Disclosure at Forbes
10:23AM  Kroger gains on higher profit; AbbVie slides on merger news at MarketWatch
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene and Orexigen - Press Releases Zacks
Mar-04-15 06:18PM  Nasdaq stocks posting largest volume increases AP +11.13%
05:30PM  Orexigen soars on drug data CNBC
04:45PM  Orexigen Soars as Interim Data on Contrave Comes to Light - Analyst Blog Zacks
03:05PM  Orexigen Therapeutics (OREX) Stock Surging Today on Heavy Volume at TheStreet
01:28PM  Wednesday's Mid-Day Movers: PhotoMedex, Career Education And More Benzinga
11:35AM  Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog Zacks
10:57AM  Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data at The Wall Street Journal
Mar-03-15 09:07PM  Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study Benzinga +31.95%
04:44PM  Orexigen Jumps on Diet Pills Heart Benefit as FDA Frowns at Bloomberg
04:44PM  Best Buy and Orexigen are big market movers AP
04:13PM  Orexigen Comments On Data Disclosure That "Disappointed" FDA at Forbes
03:36PM  Nasdaq backs off from 5,000 CNBC
03:33PM  The FDA Is Forcing Orexigen To Do A Second Safety Study Because Of Contrave Disclosures at Forbes
02:16PM  Has Orexigen Endangered Its Future To Boost Its Stock? at Forbes
02:06PM  Orexigen Released Interim Data Without Approval Of Trial Leaders at Forbes
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Mar-02-15 06:05PM  What Are The Real Economic Costs Of Obesity? at Investopedia
Feb-27-15 03:08PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Feb-26-15 09:30AM  Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Zacks
Feb-25-15 07:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 7:30 am ET today CCBN
07:07AM  Q4 2014 Orexigen Therapeutics Inc Earnings Release - Before Market Open CCBN
06:45AM  Orexigen misses 4Q profit forecasts AP
06:42AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
06:30AM  Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014 PR Newswire
Feb-23-15 08:30AM  Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-20-15 04:45PM  Orexigen Therapeutics to Host Full Year and Fourth Quarter 2014 Financial Results Conference Call and Webcast PR Newswire
03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet
Feb-10-15 04:30PM  Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog Zacks
Feb-09-15 08:06AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
08:00AM  Orexigen Provides Progress Update on Mysimba European Marketing Authorization PR Newswire
Feb-06-15 04:15PM  Orexigen Therapeutics to Speak at the Leerink Global Healthcare Conference PR Newswire
Feb-05-15 04:53PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-28-15 03:13PM  Consumer Groups Urge Europe not to Approve the Orexigen Diet Pill at The Wall Street Journal
Jan-23-15 06:20AM  Coverage initiated on Orexigen Therapeutics by RBC Capital Mkts Briefing.com
Jan-16-15 07:00AM  Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks +5.62%
Jan-14-15 01:55PM  5 Obesity Stocks Investors Are Watching Benzinga
Jan-13-15 02:22PM  Orexigen CEO: Excited about obesity drug progress CNBC -5.57%
Jan-12-15 06:16AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Jan-08-15 09:00AM  Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare Conference PR Newswire
Dec-29-14 09:39AM  Novo Nordisk to promote drug to treat obesity in United States Reuters
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP
Dec-19-14 04:24PM  New highs! The S&P 500 closes just below its prior record close... Yahoo Finance Contributors
03:22PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
08:25AM  Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators at TheStreet
07:37AM  European regulators recommend approval of Orexigen's obesity pill Reuters
07:19AM  Orexigen's Mysimba (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union PR Newswire
Dec-18-14 01:44PM  Six Biotech and Technology Stocks With Strong Technical Set-Ups at TheStreet
Dec-17-14 07:42AM  Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Yahoo Finance Blogs +7.77%
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Blogs
Dec-08-14 03:31PM  These 4 Biotech Stocks Have Been On Fire Benzinga
Dec-05-14 05:50AM  Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick Zacks
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth Mark DChief Commercial OfficerFeb 26Option Exercise1.6650,00083,00053,810Mar 02 05:34 PM
Booth Mark DChief Commercial OfficerFeb 26Sale5.6850,000284,2003,810Mar 02 05:34 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Option Exercise1.6622,64337,58722,643Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Sale6.0022,643135,8580Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Option Exercise1.667,38212,2547,382Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Sale6.007,38244,2920Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Option Exercise1.6624,00639,85024,006Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Sale5.7724,006138,5870Nov 26 05:01 PM
BOCK LOUIS CDirectorNov 18Buy5.587003,905700Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 18Buy5.586253,48727,677Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 12Buy5.5727,052150,54427,052Nov 13 09:27 AM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM
DOVEY BRIAN HDirectorApr 22Option Exercise0.004,691,4704,6917,580,065Apr 23 05:15 PM